News

Filter

Current filters:

GenzymeRare diseases

1 to 9 of 44 results

Positive Ph III clinical trial extension results for Genzyme’s Cerdelga

Positive Ph III clinical trial extension results for Genzyme’s Cerdelga

13-02-2015

French pharma major Sanofi subsidiary Genzyme has reported positive extension study data from its Phase…

BiotechnologyCerdelgaGenzymeRare diseasesResearchSanofi

Genzyme collaborates on gene therapy for rare disease that causes childhood blindness

Genzyme collaborates on gene therapy for rare disease that causes childhood blindness

25-09-2014

French pharma major Sanofi subsidiary Genzyme has entered into a research collaboration with the USA’s…

BiotechnologyFranceGenzymeOphthalmicsRare diseasesSanofi

Genzyme’s Cerdelga gets FDA approval for Gaucher disease

Genzyme’s Cerdelga gets FDA approval for Gaucher disease

20-08-2014

The US Food and Drug Administration late yesterday approved Cerdelga (eliglustat) for the long-term treatment…

ActelionBiotechnologyCerdelgaCerezymeGenzymeRare diseasesRegulationSanofiUSAZavesca

FDA expands approval of Genzyme’s Lumizyme to treat Pompe disease

FDA expands approval of Genzyme’s Lumizyme to treat Pompe disease

02-08-2014

The US Food and Drug Administration on Friday approved Lumizyme (alglucosidase alfa) for treatment of…

BiotechnologyGenzymeLumizymeMyozymeRare diseasesRegulationSanofiUSA

Genzyme to gain rights to certain Alnylam rare disease pipeline products

Genzyme to gain rights to certain Alnylam rare disease pipeline products

13-01-2014

French drug major Sanofi’s US biotech subsidiary Genzyme and Alnylam Pharmaceuticals have significantly…

Alnylam PharmaceuticalsBiotechnologyGenzymeLicensingMergers & AcquisitionspatisiranRare diseasesResearchSanofi

FDA grants priority review for Genzyme’s Cerdelga

FDA grants priority review for Genzyme’s Cerdelga

11-12-2013

The US Food and Drug Administration has granted Sanofi (Euronext: SAN) and its subsidiary Genzyme a six-month…

BiotechnologyeliglustatGenzymeNorthern EuropeRare diseasesResearch

Genzyme to invest $80 million to expand capacity for Fabrazyme

Genzyme to invest $80 million to expand capacity for Fabrazyme

15-10-2013

French drug major Sanofi’s US biotech subsidiary Genzyme says that it is investing $80 million to build…

BiotechnologyFabrazymeFinancialGenzymeNorth AmericaProductionRare diseasesSanofi

Easier access to funded enzyme replacement therapy proposed in New Zealand

20-09-2013

New Zealand’s Pharmaceutical Management Agency PHARMAC is providing greater funded access to the expensive…

Asia-PacificBiotechnologyFinancialGenzymeRare diseasesRelvar ElliptaSanofi

1 to 9 of 44 results

COMPANY SPOTLIGHT

Menarini

Back to top